BACKGROUND:Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. AIMS: To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. METHOD:A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER. RESULTS: All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups. CONCLUSIONS:Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
RCT Entities:
BACKGROUND: Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. AIMS: To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. METHOD: A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER. RESULTS: All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups. CONCLUSIONS:Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
Authors: Emily Carl; Sara M Witcraft; Brooke Y Kauffman; Eilis M Gillespie; Eni S Becker; Pim Cuijpers; Michael Van Ameringen; Jasper A J Smits; Mark B Powers Journal: Cogn Behav Ther Date: 2019-02-14
Authors: Domenic A Ciraulo; David H Barlow; Suzy Bird Gulliver; Todd Farchione; Sandra B Morissette; Barbara W Kamholz; Katherine Eisenmenger; Bonnie Brown; Eric Devine; Timothy A Brown; Clifford M Knapp Journal: Behav Res Ther Date: 2013-08-30
Authors: Murray B Stein; Mark H Pollack; Alexander Bystritsky; Jeffrey E Kelsey; Richard M Mangano Journal: Psychopharmacology (Berl) Date: 2004-07-16 Impact factor: 4.530
Authors: Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker Journal: BMC Psychiatry Date: 2014-07-02 Impact factor: 3.630